In that sense, Cai et al. (2018) showed that the GLP-1 RA lixisenatide treatment for 60 days in 12-month-old APP/PS1/Tau AD female mice promoted a decreased Aβ plaque load and p-Tau levels in the hippocampus, along with a decreased neuroinflammatory status. The gene discussed is MAPT; the disease is Alzheimer disease.